CSM Advisors LLC Lowers Stock Holdings in Humana Inc. $HUM

CSM Advisors LLC decreased its stake in shares of Humana Inc. (NYSE:HUM) by 68.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,486 shares of the insurance provider’s stock after selling 16,385 shares during the period. CSM Advisors LLC’s holdings in Humana were worth $1,947,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in HUM. Elevation Point Wealth Partners LLC purchased a new stake in shares of Humana during the 2nd quarter valued at $32,000. Mather Group LLC. purchased a new position in shares of Humana in the 3rd quarter worth $34,000. Private Wealth Management Group LLC raised its position in shares of Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after buying an additional 48 shares during the period. AlphaCore Capital LLC acquired a new position in Humana in the second quarter valued at $39,000. Finally, BOKF NA boosted its holdings in Humana by 4,125.0% in the third quarter. BOKF NA now owns 169 shares of the insurance provider’s stock valued at $44,000 after acquiring an additional 165 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insider Buying and Selling

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the acquisition, the insider owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. This trade represents a 7.47% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on HUM. JPMorgan Chase & Co. dropped their price target on Humana from $274.00 to $180.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. Morgan Stanley set a $146.00 target price on Humana in a report on Thursday, February 12th. UBS Group reissued a “neutral” rating on shares of Humana in a research report on Wednesday, February 25th. Jefferies Financial Group cut their price target on shares of Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Finally, Cantor Fitzgerald reduced their price target on shares of Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research report on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of “Hold” and a consensus target price of $225.48.

Humana Price Performance

HUM opened at $170.18 on Tuesday. Humana Inc. has a twelve month low of $163.60 and a twelve month high of $315.35. The firm has a market cap of $20.43 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 1.77 and a beta of 0.44. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a fifty day simple moving average of $210.78 and a 200 day simple moving average of $246.62.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm’s revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 27th. This represents a $3.54 annualized dividend and a dividend yield of 2.1%. Humana’s payout ratio is 36.05%.

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.